A stable pharmaceutical formulation or suspension has a pharmaceutical active agent, agave, and a dilutant. The formulation or suspension has viscosity suitable for drinking.

The present invention relates generally to a feed supplement preparation for administration to ruminant animals and, more particularly, to a formulation for an oral bovine supplement for neonatal calves that delivers naturally occurring caffeine, in a stable liquid form of elevated viscosity and optionally antioxidants and other electrolytes. A 10-40 ml liquid dose of the supplement containing green tea extract delivers a concentrated amount of caffeine of about 100-400 mg to the neonatal calf.

The present invention relates generally to a feed supplement preparation for administration to ruminant animals and, more particularly, to a formulation for an oral bovine supplement for neonatal calves that delivers naturally occurring caffeine, in a stable liquid form of elevated viscosity and optionally antioxidants and other electrolytes. A 10-40 ml liquid dose of the supplement containing green tea extract delivers a concentrated amount of caffeine of about 100-400 mg to the neonatal calf.

This is an invention of a process and combination of ingredients in producing an novel herbal energy tea that is ready to drink. This tea is composed of elderberry dandelion, rose petals and rose hips, Mexican honeysuckle, yohimbe and agave nectar. This tea is yohimbe, elderberry, and Mexican honeysuckle based. The tea is not tea leaf based. There are currently no other products on the market in the United States that are similar to this product. It is the first, a novelty. The process of making an organic drinkable herbal energy tea product also includes the distinct process of using distilled water and or spring water. This also makes the process distinct and novel, because it is the first process that does not use municipal filtered water (which may contain cross contaminants) in the production of energy tea drinks. In addition yohimbe (tree bark) is the stimulant of choice as opposed to caffeine and other market stimulants. The sum of ingredients included in the process and production work synergistically to support vital organ function.

Brewing the ingredients require a short process of initial high heat of up to 212 degrees Fahrenheit, then simmering for 1 and a half hours at a temperature of 75 degrees. After simmering, the tea goes through a double micro filtration process extracting solid waste by-products. Thereafter, sweeteners and extracts are mixed and added to the warm cooling brew arriving the product to final settle and cool ready for storage or distribution.

This is an invention of a process and combination of ingredients in producing an novel herbal energy tea that is ready to drink. This tea is composed of elderberry dandelion, rose petals and rose hips, Mexican honeysuckle, yohimbe and agave nectar. This tea is yohimbe, elderberry, and Mexican honeysuckle based. The tea is not tea leaf based. There are currently no other products on the market in the United States that are similar to this product. It is the first, a novelty. The process of making an organic drinkable herbal energy tea product also includes the distinct process of using distilled water and or spring water. This also makes the process distinct and novel, because it is the first process that does not use municipal filtered water (which may contain cross contaminants) in the production of energy tea drinks. In addition yohimbe (tree bark) is the stimulant of choice as opposed to caffeine and other market stimulants. The sum of ingredients included in the process and production work synergistically to support vital organ function.

Brewing the ingredients require a short process of initial high heat of up to 212 degrees Fahrenheit, then simmering for 1 and a half hours at a temperature of 75 degrees. After simmering, the tea goes through a double micro filtration process extracting solid waste by-products. Thereafter, sweeteners and extracts are mixed and added to the warm cooling brew arriving the product to final settle and cool ready for storage or distribution.

The invention includes a toothpaste or other orally applied product to be used at least once daily to help prevent or inhibit the acquisition of a number of infections by oral or pharyngeal tissues, particularly including the “common” cold. These compositions possess a combination of ingredients that is not found in other toothpastes or other orally applied products, and these ingredients work together to synergistically interfere with the acquisition of a number of pathogens. The toothpastes will have the usual dentifrice ingredients known to prevent tooth decay, as well as those that reduce halitosis (i.e., bad breath), and prevent gingivitis. In addition, the toothpastes will include one or more of: 1) GALALCOOL® as an individual compound, and not as an extract component; 2) zinc protoporphyrin IX; and 3) one or more other colorless or low-color tannin(s) each as an individual compound, and not as an extract component.

The invention includes a toothpaste or other orally applied product to be used at least once daily to help prevent or inhibit the acquisition of a number of infections by oral or pharyngeal tissues, particularly including the “common” cold. These compositions possess a combination of ingredients that is not found in other toothpastes or other orally applied products, and these ingredients work together to synergistically interfere with the acquisition of a number of pathogens. The toothpastes will have the usual dentifrice ingredients known to prevent tooth decay, as well as those that reduce halitosis (i.e., bad breath), and prevent gingivitis. In addition, the toothpastes will include one or more of: 1) GALALCOOL® as an individual compound, and not as an extract component; 2) zinc protoporphyrin IX; and 3) one or more other colorless or low-color tannin(s) each as an individual compound, and not as an extract component.

The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of mucin from and/or in the cornea, and methods of using the compositions to treat the eye.

The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of mucin from and/or in the cornea, and methods of using the compositions to treat the eye.

Topical pain relief compositions include a cannabinoid, terpenoid, and skin penetration system that includes dimethyl sulfoxide (DMSO) and at least one compatibilizer. The composition may be in the form of an emulsion that contains water and at least one fatty component. The composition can be used to reduce or eliminate pain by direct topical application to an affected part or region of the body. A method of treating pain may include direct topical application of the composition to a joint, ligament, muscle, tendon, or disk. The composition penetrates through the skin to provide localized pain relief where applied and provides a quantity of cannabinoid in the region of the pain instead of distributing the cannabinoid systemically and/or to the brain or central nervous system. The composition may be applied by rubbing or massaging at the treatment site and/or by a bandage, patch or other barrier layer.